Alumis Inc. Common Stock (ALMS) is a publicly traded Healthcare sector company. As of May 21, 2026, ALMS trades at $22.66 with a market cap of $2.70B and a P/E ratio of -12.17. ALMS moved +2.37% today. Year to date, ALMS is +165.22%; over the trailing twelve months it is +351.64%. Its 52-week range spans $2.76 to $30.60. Analyst consensus is strong buy with an average price target of $40.44. Rallies surfaces ALMS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Alumis’s Envudeucitinib Achieves 68% PASI 90 Response; Q1 Cash $569.5M: Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis showed Week 24 PASI 90 responses of 68.0% and 62.1% and PASI 100 rates of 41.0% and 39.5%. Alumis ended Q1 with $569.5 million cash, a $93.1 million net loss and remains on track for a Q4 2026 NDA submission and Q3 2026 SLE readout.
| Metric | Value |
|---|---|
| Price | $22.66 |
| Market Cap | $2.70B |
| P/E Ratio | -12.17 |
| EPS | $-1.78 |
| Dividend Yield | 0.00% |
| 52-Week High | $30.60 |
| 52-Week Low | $2.76 |
| Volume | 112 |
| Avg Volume | 0 |
| Revenue (TTM) | $8.40M |
| Net Income | $-237.41M |
| Gross Margin | 0.00% |
9 analysts cover ALMS: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $40.44.